Therapeutic Outcomes and Electrophysiological Biomarkers in Anti-Myelin-Associated Glycoprotein Neuropathy:A Multicenter Cohort Study in South Korea
- Author:
Young Gi MIN
1
;
Hee-Jo HAN
;
Ha Young SHIN
;
Jong-Gyu BAEK
;
Jun-Soon KIM
;
Kyung-Seok PARK
;
Seol-Hee BAEK
;
Ilhan YOO
;
So-Young HUH
;
Young Nam KWON
;
Seok-Jin CHOI
;
Sung-Min KIM
;
Yoon-Ho HONG
;
Jung-Joon SUNG
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:Journal of Clinical Neurology 2024;20(1):50-58
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:and Purpose Unlike other immune-mediated neuropathies, anti-myelin-associated glycoprotein (MAG) neuropathy is often refractory to immunotherapy. It is necessary to compare the relative efficacies of various immunotherapies and develop objective biomarkers in order to optimize its clinical management.
Methods:This study recruited 91 patients with high anti-MAG antibody titers from 7 tertiary hospitals in South Korea. We analyzed the baseline characteristics, therapeutic outcomes, and nerve conduction study (NCS) findings of 68 patients and excluded 23 false positive cases.
Results:The rate of positive responses to treatment was highest using zanubrutinib (50%) and rituximab (36.4%), followed by corticosteroids (16.7%), immunosuppressants (9.5%), intravenous immunoglobulin (5%), and plasma exchange (0%). Disability and weakness were significantly associated with multiple NCS parameters at the time of diagnosis, especially distal compound muscle action potential (CMAP) amplitudes. Moreover, the longitudinal trajectory of the average CMAP amplitudes paralleled the clinical courses, with a 16.2 percentile decrease as an optimal cutoff for predicting a clinical exacerbation (area under the receiver operating characteristic curve=0.792).
Conclusions:Our study supports the use of NCS as an objective marker for estimating disease burden and tracking clinical changes in patients with anti-MAG neuropathy. We have described the beneficial effects of rituximab and a new drug, zanubrutinib, compared with conventional immunotherapies.
